Author:
Zhang Tingting,Tian Weiwei,Wei Shuang,Lu Xinyi,An Jing,He Shaolong,Zhao Jie,Gao Zhilin,Li Li,Lian Ke,Zhou Qiang,Zhang Huilai,Wang Liang,Su Liping,Kang Huicong,Niu Ting,Zhao Ailin,Pan Jing,Cai Qingqing,Xu Zhenshu,Chen Wenming,Jing Hongmei,Li Peng,Zhao Wanhong,Cao Yang,Mi Jianqing,Chen Tao,Chen Yuan,Zou Ping,Lukacs-Kornek Veronika,Kurts Christian,Li Jian,Liu Xiansheng,Mei Qi,Zhang Yicheng,Wei Jia
Abstract
AbstractThe outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology